IGMS vs. CRVS, PRME, MNPR, TRVI, ATYR, ALLO, CMPS, KRRO, FHTX, and TNGX
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Corvus Pharmaceuticals (CRVS), Prime Medicine (PRME), Monopar Therapeutics (MNPR), Trevi Therapeutics (TRVI), Atyr PHARMA (ATYR), Allogene Therapeutics (ALLO), COMPASS Pathways (CMPS), Korro Bio (KRRO), Foghorn Therapeutics (FHTX), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.
IGM Biosciences vs.
Corvus Pharmaceuticals (NASDAQ:CRVS) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.
Corvus Pharmaceuticals has higher earnings, but lower revenue than IGM Biosciences. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Corvus Pharmaceuticals received 219 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 61.91% of users gave Corvus Pharmaceuticals an outperform vote while only 47.68% of users gave IGM Biosciences an outperform vote.
46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Corvus Pharmaceuticals presently has a consensus target price of $12.38, indicating a potential upside of 195.35%. IGM Biosciences has a consensus target price of $5.50, indicating a potential upside of 298.55%. Given IGM Biosciences' higher probable upside, analysts clearly believe IGM Biosciences is more favorable than Corvus Pharmaceuticals.
Corvus Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500.
In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 1 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat IGM Biosciences' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.
Corvus Pharmaceuticals has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,534.03%. Corvus Pharmaceuticals' return on equity of -70.71% beat IGM Biosciences' return on equity.
Summary
Corvus Pharmaceuticals beats IGM Biosciences on 13 of the 16 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:IGMS) was last updated on 2/22/2025 by MarketBeat.com Staff
